Greg Silvanouve

Greg Silvanouve asked for clarification on the additional BRINSUPRI opportunity involving 32 million COPD and asthma patients, specifically whether a clinical study is needed or how physicians can prescribe the medicine (off-label vs. on-label) to this population.

Answer

Will Lewis, Chair and CEO, clarified that Insmed is focused 'on label exclusively.' He explained that if an exacerbating COPD or asthma patient undergoes a CT scan and receives a definitive diagnosis of bronchiectasis from a pulmonologist, they become 'on label' for BRINSUPRI. He emphasized education efforts to raise suspicion among physicians and identify these patients who could benefit from an on-label prescription.

Sam on behalf of Greg Silvanouve at Mizuho asked about the physician feedback received at the recent ASRS meeting and what incremental data to expect from the full end-of-study VORONNA data presentation in September.

Answer

CEO Jay Duker described the feedback at ASRS as 'incredible' and 'positive,' with physicians excited about the new mechanism of action and the potential for a true six-month treatment extension. CMO Ramiro Ribeiro stated that the upcoming VORONNA presentation will build on previously shared data regarding BCVA, CST, and treatment burden, but did not disclose further specifics ahead of the meeting.